ERBB2 and breast cancer: Patients with loss of HER2 expression survived 99.4 months on average, whereas patients with a gain of HER2 expression survived 77.8 months after the diagnosis of metastatic BC (95% confidence interval of the mean: loss of HER2 69.1–129.7 months vs. gain of HER2 61.0–95.7 months).